Literature DB >> 1933783

Simultaneous carcinoma involving the endometrium and the ovary. A clinicopathologic, immunohistochemical, and DNA flow cytometric study of 18 cases.

J Prat1, X Matias-Guiu, J Barreto.   

Abstract

Eighteen carcinomas involving both the endometrium and the ovary were studied. Stage, size, bilaterality and pattern of ovarian involvement, histologic types and grades, presence of endometrial hyperplasia or ovarian endometriosis, myometrial, tubal, lymphatic and blood vessel invasion, and follow-up of the patients were all evaluated. Accordingly, the cases were classified as follows: Group A (nine cases), two separate primary tumors; and Group B (nine cases), uterine primaries with ovarian metastasis or ovarian primaries with uterine metastasis. Immunohistochemical stains (CAM 5.2, wide-spectrum keratin, vimentin, carcinoembryonic antigen (CEA), CA 12.5, CA 19.9) were performed in all cases. Flow cytometric determination of nuclear DNA was done in 13 (seven Group A and six Group B tumors). Of the nine cases with independent primary tumors, seven showed different immunohistochemical profiles in the ovarian and uterine tumors, whereas only four of the nine metastatic ones had similar staining characteristics. Five cases with independent primary tumors, but only one of the metastatic group, exhibited different aneuploid stemlines in the endometrial and ovarian tumors. The other seven (two independent and five metastatic) cases had similar DNA indexes in both tumors. Immunohistochemical and DNA flow cytometric study may be of some value for the distinction between metastatic and independent tumors, but differential diagnosis must presently rely largely upon conventional clinicopathologic criteria.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933783     DOI: 10.1002/1097-0142(19911201)68:11<2455::aid-cncr2820681122>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors.

Authors:  Mohamed M Desouki; Sarah J Kallas; Dineo Khabele; Marta A Crispens; Omar Hameed; Oluwole Fadare
Journal:  Int J Gynecol Pathol       Date:  2014-05       Impact factor: 2.762

2.  Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.

Authors:  Gulisa Turashvili; Natalia R Gómez-Hidalgo; Jessica Flynn; Mithat Gonen; Mario M Leitao; Robert A Soslow; Rajmohan Murali
Journal:  Gynecol Oncol       Date:  2018-11-06       Impact factor: 5.482

3.  Endometrial Cancer: Comparison of Patients with Synchronous Primary Carcinoma of the Endometrium and Ovary vs. Endometrial Carcinoma with Ovarian Metastases.

Authors:  I Juhasz-Böss; T Fehm; S Becker; R Rothmund; B Krämer; A Staebler; D Wallwiener; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-08-16       Impact factor: 2.915

4.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  [Differential diagnosis of ovarian metastases].

Authors:  S Hauptmann
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

6.  Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.

Authors:  Anne M Schultheis; Charlotte K Y Ng; Maria R De Filippo; Salvatore Piscuoglio; Gabriel S Macedo; Sonia Gatius; Belen Perez Mies; Robert A Soslow; Raymond S Lim; Agnes Viale; Kety H Huberman; Jose C Palacios; Jorge S Reis-Filho; Xavier Matias-Guiu; Britta Weigelt
Journal:  J Natl Cancer Inst       Date:  2016-02-01       Impact factor: 13.506

Review 7.  Multiple primary cancer in the female genital system: Two rare case reports and a literature review.

Authors:  Wei Chai; Fengyan Gong; Wenlei Zhang; Yan Wen; Lifeng Cui
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.